“Funding was highly concentrated, with HIV/AIDS, TB, and malaria receiving nearly 80% of the total (see Table 2). Other equally high-burden diseases as measured by DALYs (disability-adjusted life years), such as pneumonia and the diarrhoeal illnesses, collectively received less than 6% of total funding.
Overall, product R&D investment was heavily focused on drugs and vaccines. Investment in new diagnostics was patchy, while platform technologies applicable to many diseases, for instance vaccine adjuvants, diagnostic platforms, and delivery technologies, received less than 0.4% of total R&D investment.”
[There is a standard caveat regarding DALYs/using DALYs in funding in the Discussion.]
PLoS Medicine 2009
[First G-FINDER report]